Natera (NASDAQ:NTRA) released its earnings results on Thursday. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03), Briefing.com reports. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The business had revenue of $65.30 million for the quarter, compared to analyst estimates of $66.42 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. The business’s revenue for the quarter was up 16.8% on a year-over-year basis. Natera updated its FY 2018 guidance to EPS.
NASDAQ NTRA traded down $3.83 on Friday, hitting $16.80. 4,391,474 shares of the company’s stock were exchanged, compared to its average volume of 457,138. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -7.00 and a beta of 2.11.
In related news, CEO Matthew Rabinowitz sold 185,163 shares of the company’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $25.13, for a total value of $4,653,146.19. Following the sale, the chief executive officer now owns 1,701,686 shares in the company, valued at approximately $42,763,369.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Steven Leonard Chapman sold 45,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the sale, the chief operating officer now owns 16,628 shares in the company, valued at approximately $418,360.48. The disclosure for this sale can be found here. Insiders have sold a total of 2,014,988 shares of company stock worth $48,674,710 in the last quarter. 13.18% of the stock is currently owned by insiders.
Several equities analysts have issued reports on NTRA shares. Piper Jaffray Companies boosted their target price on Natera to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, August 9th. Canaccord Genuity boosted their target price on Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 16th. TheStreet upgraded Natera from a “d” rating to a “c-” rating in a research report on Thursday, August 9th. BidaskClub upgraded Natera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 17th. Finally, Zacks Investment Research cut Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $28.25.
COPYRIGHT VIOLATION NOTICE: “Natera (NTRA) Issues Quarterly Earnings Results” was first posted by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/11/natera-ntra-issues-quarterly-earnings-results.html.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.